About this trial
This study is a prospective, randomized, double-blind, phase II interventional clinical trial evaluating the effect of perioperative intravenous lidocaine infusion compared with high-dose dexamethasone on postoperative immune response and clinical outcomes in patients undergoing surgery for colon cancer. Patients with colon cancer often experience postoperative inflammatory and immune changes that may influence recovery and complications. The aim of this study is to assess whether perioperative lidocaine infusion may improve postoperative immune function and clinical recovery compared with standard perioperative anti-inflammatory treatment. Participants will be randomly assigned to receive either intravenous lidocaine infusion or high-dose dexamethasone during the perioperative period. Immune response markers and postoperative clinical outcomes will be evaluated. The results of this trial may contribute to improved perioperative management and recovery strategies for patients undergoing surgery for colon cancer.
Eligibility criteria
Qualifiers
Adult patients aged 18 years or older
Histologically confirmed colon cancer
Scheduled for elective surgical resection of colon cancer
Eligible for perioperative treatment with study medication (lidocaine, dexamethasone, or placebo) according to the protocol
Disqualifiers
Known allergy or hypersensitivity to lidocaine, dexamethasone, or any excipients
Severe hepatic impairment
Severe renal impairment
Severe cardiac conduction disorders or clinically significant arrhythmias
Trial design
Treatments tested in this trial
- Lidocaine
- Dexamethasone
- Placebo